CTXRWのチャート
CTXRWの企業情報
| symbol | CTXRW |
|---|---|
| 会社名 | |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― |
| 概要 | 事業概要 -- |
| 本社所在地 | -- |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | -- |
| 市場名 | -- |
| ipoyear | ―年 |
| 従業員数 | - |
| url | ― |
| nasdaq_url | https://www.nasdaq.com/symbol/ctxrw |
| adr_tso | ― |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 0.2432 |
| 時価総額（marketcap） | 0 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
CTXRWのテクニカル分析
CTXRWのニュース
Tiling stocks: Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX -2.87%), Citius Pharmaceuticals, Inc. (NASDAQ:CTXR 3.52%) 2022/08/02 23:48:56 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Tiling stocks: Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX -2.87%), Citius Pharmaceuticals, Inc. (NASDAQ:CTXR 3.52%) appeared first on Stocks Equity .
Fascinating stocks: Helbiz, Inc. (NASDAQ:HLBZ -7.58%), Citius Pharmaceuticals, Inc. (NASDAQ:CTXR -0.59%) 2022/07/27 00:55:13 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Fascinating stocks: Helbiz, Inc. (NASDAQ:HLBZ -7.58%), Citius Pharmaceuticals, Inc. (NASDAQ:CTXR -0.59%) appeared first on Stocks Equity .
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Is Expected To Soar To Higher Prices In The Months To Come. 2022/07/26 12:30:00 Marketing Sentinel
In the last trading session, 1.01 million Citius Pharmaceuticals Inc. (NASDAQ:CTXR) shares changed hands as the company’s beta touched 1.53. With the company’s per share price at $0.90 changed hands at -$0.08 or -8.67% during last session, the market valuation stood at $116.92M. CTXR’s last price was a discount, traded about -161.11% off its 52-week … Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Is Expected To Soar To Higher Prices In The Months To Come. Read More »
Citius Pharmaceuticals Inc. (NASDAQ: CTXR): Should Value Hunters Buy Stock? 2022/07/25 15:00:00 Stocks Register
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) price closed higher on Friday, July 22, jumping 12.20% above its previous close. A look at the daily price movement shows that the last close reads $0.88, with intraday deals fluctuated between $0.8601 and $1.015. The company’s 5Y monthly beta was ticking 1.41. Taking into account the 52-week price action we … Citius Pharmaceuticals Inc. (NASDAQ: CTXR): Should Value Hunters Buy Stock? Read More »
Astonishing stocks: Citius Pharmaceuticals, Inc. (NASDAQ:CTXR -2.10%), Happiness Development Group Limited (NASDAQ:HAPP 3.23%) 2022/07/22 00:45:57 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Astonishing stocks: Citius Pharmaceuticals, Inc. (NASDAQ:CTXR -2.10%), Happiness Development Group Limited (NASDAQ:HAPP 3.23%) appeared first on Stocks Equity .
Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm 2022/05/25 14:13:01 Benzinga
Citius Pharmaceuticals Inc (NASDAQ: CTXR ) plans to form a new company (NewCo) focused on developing and commercializing I/ONTAK. A Phase 3 trial was completed in December 2021, and a biologics license application (BLA) is being planned for submission in the second half of 2022. The Company''s other pipeline assets, including Mino-Lok, would remain at Citius. Citius would continue to trade on the Nasdaq exchange … Full story available on Benzinga.com
Citius Pharma to spinoff its immunotherapy I/ONTAK into a new publicly-traded company 2022/05/25 13:05:51 Seeking Alpha
Late-stage biopharmaceutical company Citius Pharmaceuticals (CTXR) on Wednesday said it plans to split into two separate publicly-traded entities.CTXR said it would form a new…
Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022 2022/05/18 13:30:00 PR Newswire
CRANFORD, N.J., May 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it will present at the H.C. Wainwright…
Short Interest in Citius Pharmaceuticals, Inc. Expands By 25.0% 2022/05/17 16:49:09 Business Mag
Citius Pharmaceuticals, Inc. was the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 13,230,000 shares, a growth…
Citius Pharmaceuticals GAAP EPS of -$0.05 beats by $0.02 2022/05/12 20:38:12 Seeking Alpha
Citius Pharmaceuticals press release (CTXR): Q2 GAAP EPS of -$0.05 beats by $0.02.Topline results of Phase 3 trial in cancer immunotherapy I/ONTAK consistent with prior formulation;…
Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma 2021/12/06 14:15:00 PR Newswire
CRANFORD, N.J., Dec. 6, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective
Up to Date Stock in Review: Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), ENDRA Life Sciences Inc. (NASDAQ:NDRA) 2021/11/23 11:52:53 Stock Equity
Citius Pharmaceuticals, Inc. (CTXR) with the stream of -2.05% also noticed, India ENDRA Life Sciences Inc. (NDRA) encountered a rapid change of -9.11% in the last hour of Monday’s trading … The post Up to Date Stock in Review: Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), ENDRA Life Sciences Inc. (NASDAQ:NDRA) appeared first on Stocks Equity .
Citius Pharmaceuticals (NASDAQ:CTXR) Stock Rating Upgraded by Zacks Investment Research 2021/11/11 08:40:41 Dakota Financial News
Citius Pharmaceuticals (NASDAQ:CTXR) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective []
Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls 2021/11/05 13:15:00 PR Newswire
CRANFORD, N.J., Nov. 5, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective